Answers are grounded in this paper and cite their sources.
Objective: The aim of this study is to evaluate the prognostic factors of adjuvant or definitive radiotherapy (RT) and/or chemoradiotherapy (CRT) in patients with squamous cell head and neck (HN) tumor treated in our clinic. Methods:The prognostic factors in the patients who were treated between February 2017 and May 2021 were retrospectively evaluated.A total of 78 patients diagnosed with HN cancer were included in the study.RT was applied to tumor/tumor lodge lymphatics at a dose of 54-70 gray.The prognostic factors, side effects, and overall survival in patients were noted and evaluated.Results: Of a total of 78 patients, 15 (19.2%) were female and 63 (80.8%) were male.The most common tumor location in the patients was larynx (53.8%), followed by oral cavity (24.4%), and oropharynx (15.4%).Twenty-seven (34.6%) patients were in the T2 stage.Additionally, most of the patients were N0 (39 patients, 50%), and 29 (37.2%)patients were N2.Forty-three (55.1%) patients underwent surgery.Forty-three (55.1%) patients received adjuvant RT.Concomitant chemotherapy with RT was administered to 46 (59%) patients.In all groups, significant differences were found in hemoglobin and platelets before and after RT.Borderline significant in white blood cells.N stage of the tumor, smoking habit, and tumor localization were found to be significant for survival. Conclusion:In the treatment of HN cancers, disease-free survival and a functional life in which organs at risk are protected as much as possible are aimed.RT/CRT is a highly toxic, long-term, and organ-preserving therapy.One of the main goals is to provide a survival advantage by increasing local control and protecting patients from side effects.
No takes yet. Share an insight, caveat, or question.
Soydemir et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: